Touch Medical Media coverage of data presented at EADV 2023:
BE HEARD I and II, were phase 3 clinical trials that investigated the efficacy and safety of bimekizumab for the treatment of hidradenitis suppurativa (HS). In this interview, we were delighted to speak with Prof. Christos C. Zouboulis (Brandenburg Medical School Theodor Fontane, Neuruppin, Germany) to discuss the rationale for investigating bimekizumab in HS, the aims, methodology and findings from his analysis of BE HEARD I and II, and the next steps for the development of bimekizumab.
The abstract ‘Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: Analysis of pooled data from BE HEARD I and II phase 3, randomised, double-blind, placebo-controlled, multicentre studies‘ (Abstract N°: 3262) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.
Questions
- What are the latest updates to the treatment guidelines for hidradenitis suppurativa (HS)?
- What is the mechanism of action and rationale for investigating bimekizumab for the treatment of HS?
- What were the aims and methodology of your pooled analysis of BE HEARD I and II?
- What were the efficacy and safety findings from your analysis?
- What will be the next steps in the clinical development of bimekizumab in this indication?
Disclosures: Christos C. Zouboulis has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.
Filmed in coverage of the EADV Annual Meeting.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
Click here for more content on hidradenitis suppurativa & for further EADV 2023 highlights visit here.
